Streetbeat News

Products Services

NICE

Limango has chosen NICE CXone, a cloud contact center platform, to enhance their customer experience operations. This transition from an on-premise solution to the cloud aims to increase operational efficiency, provide better insights into daily operations, reduce reliance on the IT department, and improve overall customer experiences.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:11 pm

WKSP

Worksport Ltd. (NASDAQ: WKSP) has announced that its COR battery system has entered the Test Phase, indicating progress towards the anticipated Alpha Release. The system, designed for use in pickup trucks and independently, will undergo extensive testing in various conditions to ensure resilience and durability. The feedback from the Alpha Release will inform further improvements, with the goal of a Mass Market Release of the COR battery system and the SOLIS solar cover.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:09 pm

TGB

Taseko Mines Limited has announced the appointment of Richard Tremblay as Chief Operating Officer and Terry Morris as Vice President, Operations. Tremblay, with over 30 years of experience, has been with Taseko since 2014 and has played a key role in the Florence Copper Project. Morris brings nearly 20 years of experience and has held roles at Barrick Gold, Peabody Australia, Westmoreland Coal, and Teck Resources. The company is focusing on becoming a North American multi-asset copper producer, with the Florence Copper project expected to commence commercial operations in 2025.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:07 pm

DARE

Daré Bioscience has extended its exclusive partnership agreement with Premier Research to continue receiving contract research organization services in the US for its reproductive health portfolio. The original agreement was with Health Decisions, Inc., which Premier Research acquired in 2021.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:06 pm

HSCS

HeartSciences has closed license agreements with the Icahn School of Medicine at Mount Sinai to develop and commercialize AI-powered ECG algorithms. This partnership makes Icahn Mount Sinai a shareholder in HeartSciences. The company aims to transform cardiovascular disease detection using AI-ECG algorithms, leveraging a cloud-based platform compatible with existing ECG devices. The technology was developed by Icahn Mount Sinai faculty, who have a financial interest in HeartSciences.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:06 pm

ASND

Ascendis Pharma has received approval from the European Commission for YORVIPATH, a treatment for adults with chronic hypoparathyroidism. This marks a significant milestone for the company as it expands its product offerings in the European market.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:05 pm

AVXL

Anavex Life Sciences Corp. has started the regulatory submission process for its oral drug Blarcamesine with the European Medicines Agency (EMA) for the treatment of Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:04 pm

MIRA

MIRA Pharmaceuticals has entered into an exclusive licensing agreement for an oral ketamine analog, Ketamir-2. Additionally, MIRALOGX has extended a $3M line of credit to MIRA Pharmaceuticals to fund the initial development of Ketamir-2.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 1:02 pm

CYBN

Cybin is set to discuss Phase 2 safety and efficacy data for CYB003, a deuterated psilocybin analog for Major Depressive Disorder, during an R&D Investor Briefing in New York City on November 30, 2023, at 10:00 A.M. ET.

Portfolio Pulse from Benzinga Newsdesk

November 20, 2023 | 12:58 pm

MDT

The FDA has approved Medtronic plc's Symplicity Spyral renal denervation system for treating hypertension. Despite initial doubts from the FDA Circulatory System Devices Panel, which was divided on the benefit/risk profile, the device will now be commercialized by Medtronic. The Symplicity procedure is minimally invasive and is already approved in over 70 countries. Medtronic's stock (MDT) rose 1.12% in premarket trading following the announcement.

Portfolio Pulse from Vandana Singh

November 20, 2023 | 12:57 pm